Par Drugs and Chemicals
- Market cap
- ₹ 129 Cr.
- P/E
- 9.8x
- P/B
- 1.15x
- 52-week range
- 78.05 – 180
- ROE
- 14%
- ROCE
- 14%
- Dividend yield
- 0%
- Debt / equity
- 0
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE
About
Par Drugs and Chemicals Limited is an India-based company engaged in manufacturing of active pharma ingredients (APIs) and fine chemicals for the domestic market as well as for exports to international markets. The Company manufactures a diverse range of antacid molecules. The Company’s products include magnesium hydroxide, magnesium trisilicate, magnesium carbonate, light magnesium oxide, magnesium oxide heavy, magnesium oxide USP, dried aluminum hydroxide gel, magaldrate, magnesium aluminum silicate hydrated, alma gate, hydrotalcite, aluminum hydroxide magnesium carbonate co-dried gel, aluminum-magnesium silicate BP, sodium aluminum silicate, precipitated silica, magnesium silicate, amorphous, colloidal silicon dioxide, and sucralfate USP. The Company owns and operates its manufacturing facilities at Bhavnagar in Gujarat. It has over four manufacturing blocks at Bhavnagar, which are for different products, having a capacity of approximately 9,700 metric tons per annum.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Par Drugs and Chemicals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)9.8 against a typical 34.3: cheaper than most peers (1st = cheapest).20th of 220
- Sales growth+6.4% against a typical +15.6% from a year earlier.127th of 197
- Profit growth−86.9% against a typical +18.9% from a year earlier.144th of 160
- Share price, 3 months+19.9% against a typical −0.5%.35th of 200
- Size₹ 129.2 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).137th of 199
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 29 Oct 2026Upcoming | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2026 and other business matters |
| 22 Aug 2026 | Other business matters | To consider other business matters |
| 8 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 14 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 10 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 13 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 29 Aug 2025 | Other business matters | To consider other business matters |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 43 | 51 | 46 | 50 | 48 | 40 | 49 | 53 | 63 | 63 | 70 | 57 |
| Expenses | 37 | 45 | 41 | 42 | 41 | 36 | 42 | 46 | 55 | 56 | 65 | 52 |
| Operating Profit | 5 | 6 | 6 | 9 | 7 | 4 | 7 | 7 | 8 | 7 | 5 | 4 |
| OPM % | 12.4% | 11.7% | 12.5% | 17.2% | 15% | 10.6% | 13.5% | 13.9% | 12.9% | 10.9% | 7% | 7.6% |
| Other Income | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | −0 | 2 | 0 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 2 | 3 | 3 | 5 | 5 | 1 | 4 | 4 | 5 | 3 | 3 | 1 |
| Tax % | 20.1% | 25.9% | 19.4% | 26.3% | 29.8% | 16.7% | 26.1% | 26.5% | 30.3% | 16.6% | 27.1% | 28.3% |
| Net Profit | 2 | 2 | 2 | 4 | 3 | 1 | 3 | 3 | 4 | 3 | 2 | 0 |
| EPS in Rs | 1.63 | 1.9 | 1.95 | 3.47 | 2.97 | 1.05 | 2.54 | 2.85 | 3.16 | 2.36 | 1.9 | 0.37 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 13%
- 5 Years
- 23%
- 3 Years
- 14%
- TTM
- 32%
- 10 Years
- 18%
- 5 Years
- 105%
- 3 Years
- 14%
- TTM
- −7%
- 10 Years
- 14%
- 5 Years
- 37%
- 3 Years
- 11%
- TTM
- —
- 10 Years
- 11%
- 5 Years
- 15%
- 3 Years
- 15%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Par Drugs and Chemicals | ₹ 114.96 | ₹ 129 Cr. | 9.8x | 1.2x | 14% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Falgun Vallabhbhai Savani
- Chairman of the Board, Managing Director, Executive Director
- Jignesh Vallabhbhai Savani
- Executive Director and Chief Executive Officer
- Chintan Pratapbhai Chauhan
- Chief Financial Officer
- Sanket Bhupendrabhai Trivedi
- Company Secretary and Compliance Officer
Prices are delayed and for information only. Nothing on this page is investment advice.